Tamarind shell is rich in flavonoids and exhibits good biological activities. In this study, we aimed to analyze the chemical composition of tamarind shell extract (TSE), and to investigate antioxidant capacity of TSE in vitro and in vivo. The tamarind shells were extracted with 95% ethanol refluxing extraction, and chemical constituents were determined by ultra-performance chromatography–electrospray tandem mass spectrometry (UPLC-MS/MS). The free radical scavenging activity of TSE in vitro was evaluated using the oxygen radical absorbance capacity (ORAC) method. The antioxidative effects of TSE were further assessed in 2,2-azobis (2-amidinopropane) dihydrochloride (AAPH)-stimulated ADTC5 cells and tert-butyl hydroperoxide (t-BHP)-exposed zebrafish. A total of eight flavonoids were detected in TSE, including (+)-catechin, taxifolin, myricetin, eriodictyol, luteolin, morin, apigenin, and naringenin, with the contents of 5.287, 8.419, 4.042, 6.583, 3.421, 4.651, 0.2027, and 0.6234 mg/g, respectively. The ORAC assay revealed TSE and these flavonoids had strong free radical scavenging activity in vitro. In addition, TSE significantly decreased the ROS and MDA levels but restored the SOD activity in AAPH-treated ATDC5 cells and t-BHP-exposed zebrafish. The flavonoids also showed excellent antioxidative activities against oxidative damage in ATDC5 cells and zebrafish. Overall, the study suggests the free radical scavenging capacity and antioxidant potential of TSE and its primary flavonoids in vitro and in vivo and will provide a theoretical basis for the development and utilization of tamarind shell.

Alcohol liver disease (ALD) is one of the leading outcomes of acute and chronic liver injury. Accumulative evidence has confirmed that oxidative stress is involved in the development of ALD. In this study, we used chick embryos to establish ALD model to study the hepatoprotective effects of tamarind shell exttract (TSE). Chick embryos received 25% ethanol (75 μL) and TSE (250, 500, 750 μg/egg/75 μL) from embryonic development day (EDD) 5.5. Both ethanol and TSE were administrated every two days until EDD15. Ethanol-exposed zebrafish and HepG2 cell model were also employed. The results suggested that TSE effectively reversed the pathological changes, liver dysfunction and ethanol-metabolic enzyme disorder in ethanol-treated chick embryo liver, zebrafish and HepG2 cells. TSE suppressed the excessive reactive oxygen species (ROS) in zebrafish and HepG2 cells, as well as rebuilt the irrupted mitochondrial membrane potential. Meanwhile, the declined antioxidative activity of glutathione peroxidase (GPx) and superoxide dismutase (SOD), together with the content of total glutathione (T-GSH) were recovered by TSE. Moreover, TSE upregulated nuclear factor erythroid 2—related factor 2 (NRF2) and heme oxyense-1 (HO-1) expression in protein and mRNA level. All the phenomena suggested that TSE attenuated ALD through activating NRF2 to repress the oxidative stress induced by ethanol.

Myo-inositol oxygenase (MIOX), as the sole enzyme catalyzing myo-inositol (MI) catabolism in mammals, plays a central role in maintaining intracellular MI homeostasis. Dysregulation of MIOX activity disrupts MI metabolic balance, leading to pathological processes including oxidative stress, inflammation, and ferroptosis, which subsequently induce multiple diseases such as metabolic syndrome, neurological disorders, tumors, and reproductive/developmental disorders. This article systematically reviews the structure and function of MIOX as well as the pathological consequences arising from its dysregulation. Although its pathological significance is increasingly recognized, the molecular mechanisms of MIOX in many diseases have not been fully elucidated, and targeted modulators of MIOX are lacking. Future research should focus on the in-depth elucidation of the pathogenic mechanisms of MIOX disorders and the development of MIOX modulators, thereby providing precise therapeutic strategies for related diseases.

Background/Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver disease with no specific therapeutics. Wuling Powder (WLP) is a classic traditional Chinese medicine prescription with therapeutic potential against MASLD, yet its molecular mechanism remains unclear. This study aims to elucidate the mechanism and possible effective substances of WLP in the treatment of MASLD. Methods: A rat MASLD model was established via high-fat diet feeding to evaluate WLP’s efficacy. Untargeted metabolomics and 16S rRNA sequencing were used to explore the effects of WLP on metabolism and gut microbiota in vivo. Serum pharmacochemistry combined with metabolomics was used to analyze the key active components and core targets of WLP against MASLD, and molecular docking and cell experiments were used to verify the relationship between them. Results: WLP reduced hepatic lipid accumulation and pathological damage, improved lipid levels in blood liver, enhanced antioxidant capacity, and alleviated inflammation in MASLD rats. Mechanistically, WLP regulated 19 metabolic pathways. It also decreased the Firmicutes/Bacteroidota ratio and reduced the abundance of potential pathogenic bacteria (Romboutsia and Turicibacter). Thirty-one WLP-derived components were identified in serum, 13 of which were key active components for treating MASLD. These components, especially 11-deoxyalisol A and 8β-methoxyatractylenolide I, alleviated hepatic steatosis by downregulating NOS2 and PLA2G2A expression. Conclusions: The alleviation of MASLD by WLP was mediated by the regulation of 8 metabolic pathways, alterations in the abundance of Romboutsia and Turicibacter, and the restoration of 20 metabolite levels, an effect primarily ascribed to 13 distinct pharmacodynamic components derived from WLP.